sumatriptan has been researched along with Cranial Nerve Diseases in 2 studies
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.
Cranial Nerve Diseases: Disorders of one or more of the twelve cranial nerves. With the exception of the optic and olfactory nerves, this includes disorders of the brain stem nuclei from which the cranial nerves originate or terminate.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Use of sumatriptan improved the quality of recovery as measured by the QoR-40 and reduction of headache at 24 h after surgery." | 9.22 | Sumatriptan improves postoperative quality of recovery and reduces postcraniotomy headache after cranial nerve decompression. ( Bailey, T; Li, L; Manninen, PH; Tymianski, M; Venkatraghavan, L, 2016) |
| "Use of sumatriptan improved the quality of recovery as measured by the QoR-40 and reduction of headache at 24 h after surgery." | 5.22 | Sumatriptan improves postoperative quality of recovery and reduces postcraniotomy headache after cranial nerve decompression. ( Bailey, T; Li, L; Manninen, PH; Tymianski, M; Venkatraghavan, L, 2016) |
| "The antimigraine drugs sumatriptan and dihydroergotamine block the development of plasma extravasation and ultrastructural changes, as well as plasma calcitonin gene-related peptide (CGRP) increase in the superior sagittal sinus following electrical trigeminal ganglion stimulation." | 2.38 | The trigemino-vascular system and migraine. ( Buzzi, MG; Moskowitz, MA, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Venkatraghavan, L | 1 |
| Li, L | 1 |
| Bailey, T | 1 |
| Manninen, PH | 1 |
| Tymianski, M | 1 |
| Buzzi, MG | 1 |
| Moskowitz, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Sumatriptan on the Postoperative Quality of Recovery After Elective Minimally Invasive Craniotomy[NCT01632657] | 40 participants (Actual) | Interventional | 2012-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for sumatriptan and Cranial Nerve Diseases
| Article | Year |
|---|---|
The trigemino-vascular system and migraine.
Topics: Blood Proteins; Calcitonin Gene-Related Peptide; Cerebrovascular Disorders; Cranial Nerve Diseases; | 1992 |
1 trial available for sumatriptan and Cranial Nerve Diseases
| Article | Year |
|---|---|
Sumatriptan improves postoperative quality of recovery and reduces postcraniotomy headache after cranial nerve decompression.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cranial Nerve Diseases; Cranial Nerves; Double-Blind Met | 2016 |